VersaViewer

The VersaViewer is a medical diagnosis software designed to assist trained healthcare professionals by processing and analyzing 2D, 3D, and 4D medical images across various modalities. Its methodology incorporates advanced image rendering and measurement capabilities, including deep learning-based multi-organ segmentation, developed under stringent quality system regulations to ensure its safety and effectiveness for clinical diagnostic use.

The VersaViewer, a medical image management and processing system developed by GE Medical Systems SCS, has received clearance from the U.S. Food & Drug Administration (FDA) on April 21, 2025. This decision, based on the agency's determination that the VersaViewer is substantially equivalent to existing legally marketed devices, permits its marketing provided it adheres to applicable general controls, registration, good manufacturing practices, and labeling requirements.This medical diagnosis software is designed for trained healthcare professionals to process and analyze 2D, 3D, and 4D medical images from diverse modalities, thereby assisting in clinical diagnosis. Its advanced features include customizable layouts, comprehensive measurement capabilities, and various image rendering options, notably incorporating deep learning-based multi-organ segmentation. The device's development adhered to stringent quality system regulations and underwent thorough testing, validating its safety and effectiveness for its intended diagnostic applications.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific imaging modalities (e.g., CT, MRI, X-ray, Ultrasound) has the VersaViewer been validated for, and what are the performance characteristics (e.g., accuracy, precision) for each?; Can GE Medical Systems SCS provide details on the specific deep learning models used for multi-organ segmentation, including training data characteristics, validation metrics, and any potential biases or limitations?; How does the VersaViewer's "substantial equivalence" translate into clinical benefits or workflow improvements compared to the predicate devices it was compared against?; What are the post-market surveillance plans for the VersaViewer, particularly regarding the performance of its deep learning algorithms in real-world clinical settings and across diverse patient populations?; Are there any known contraindications, specific user training requirements, or hardware/software compatibility prerequisites for the optimal and safe operation of the VersaViewer in a clinical environment?